Tevogen Bio Enhances Microsoft Partnership to Incorporate AI in Preclinical Drug Development

Tevogen Bio (Tevogen), a clinical-stage biotech company specializing in immunotherapy, has announced a strategic partnership with Microsoft for Startups to leverage artificial intelligence (AI) in drug development. This collaboration aims to overhaul traditional methods, potentially reducing the current development timeline of 10-12 years and costs ranging from $1-3 billion. Tevogen’s AI initiative, branded as Tevogen.AI, will focus on two primary goals: accelerating drug development and lowering associated costs by applying machine learning to existing processes, and developing proprietary algorithms using Microsoft's leading AI tools to decode genetic and T cell interactions.

The first goal of Tevogen.AI is to enhance its ExacTcell™ pre-clinical pipeline by utilizing machine learning to conduct simulations based on successful trial outcomes of TVGN 489. This technology will enable Tevogen’s research team to analyze extensive genomic datasets, leading to quicker and more precise target identification. The second goal involves using Microsoft’s advanced AI tools to create algorithms that decode the interactions between human leukocyte antigens (HLA) and T cells. This will help Tevogen gain a deeper understanding of immune responses and discover new therapeutic opportunities, particularly in areas where data is currently limited.

Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, emphasized that resources from Microsoft have been instrumental in identifying the tools necessary to build robust data pipelines. These pipelines aggregate and normalize datasets across the viral spectrum, enhancing the efficiency of machine learning models and speeding up target selection processes. This refined data will then be incorporated into their predictive AI technology, addressing gaps where data is insufficient and identifying key interactions that have not been previously observed. Tevogen.AI will continue to collaborate with Microsoft to advance predictive modeling by leveraging their expertise.

Dr. Neal Flomenberg, Chief Scientific Officer of Tevogen Bio, highlighted that the partnership with Microsoft is expected to initially reduce development timelines by approximately 10%, with potential automation enabling a reduction of up to 30%. This preclinical modeling not only accelerates processes but also improves accuracy, resulting in significant cost savings. These advancements align with Tevogen’s mission to bring transformative therapies to market more swiftly and cost-effectively.

Tevogen Bio specializes in developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious diseases and cancers, addressing substantial unmet needs in large patient populations. The leadership at Tevogen believes that the sustainability and commercial success of healthcare innovations depend on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial and holds key intellectual property assets, including three granted patents and numerous pending patents, two of which are related to artificial intelligence.

Driven by a team of experienced industry leaders and scientists with extensive drug development and global product launch experience, Tevogen aims to make personalized therapeutics accessible. The company is committed to pioneering the next frontier of medicine by employing disruptive business models and leveraging AI to foster medical innovation.